BioXcell BE0101小鼠PD-L1單克隆抗體

BioXcell InVivoMab anti-mouse PD-L1 (B7-H1) 10F.9G2單克隆抗體與小鼠PD-L1（也稱為B7-H1或CD274）反應。PD-L1是屬于Ig超家族的B7家族的I型跨膜蛋白，分子量為40kDa。PD-L1在T淋巴細胞、B淋巴細胞、NK細胞、樹突狀細胞以及IFNγ刺激的單核細胞、上皮細胞和內皮細胞上表達。PD-L1與CD4和CD8胸腺細胞以及活化的T和B淋巴細胞和骨髓細胞上的受體PD-1結合。PD-L1與PD-1的結合導致抑制TCR介導的T細胞增殖和細胞因子產生。PD-L1被認為在腫瘤免疫逃避中起著重要作用。誘導的PD-L1表達在許多腫瘤中很常見，并導致腫瘤細胞對CD8 T細胞介導的裂解的抗性增加。在黑色素瘤的小鼠模型中，可以通過用阻斷PD-L1和PD-1之間相互作用的抗體處理來暫時腫瘤生長。BioXcell InVivoMab anti-mouse PD-L1 (B7-H1) 10F.9G2抗體已被證明可以阻斷PD-L1和PD-1之間以及PD-L1和B7-1之間的相互作用（CD80）。

(BioXcell BE0101小鼠PD-L1單克隆抗體實驗圖)

產品詳情：

產品名稱 InVivoMAb anti-mouse PD-L1 (B7-H1)

產品貨號 BE0101

產品規格 1/5/25/50/100mg

反應種屬 Mouse

克隆號 10F.9G2

同種型 Rat IgG2a, κ

免疫原 Mouse CD274

實驗應用

in vivo PD-L1 blockade

Immunofluorescence

Immunohistochemistry (frozen)

Flow cytometry

Western blot

產品形式 PBS, pH 6.5,Contains no stabilizers or preservatives

純度 >95%, Determined by SDS-PAGE

無菌處理 0.2 μm filtration

純化方式 Protein G

RRID AB_10949073

分子量 150 kDa

保存條件 抗體原液保存在4°C，不能冷凍保存。

推薦同型對照

InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin（貨號BE0090）

推薦抗體稀釋液

InVivoPure pH 6.5 Dilution Buffer（貨號IP0065）

該產品自上市已被多篇SCI文獻引用，品質有保證，以下是部分已發表的文獻引用：

應用 文章

體內PD-L1信號阻斷

(in vivo PD-L1 blockade)

1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100.

2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells' Immunity 49(2): 247-263 e247.

3. Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia reperfusion injury' J Immunol 194(1): 325-333.

4. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help' Nat Commun 6: 7994.

5. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641.

6. Tkachev, V., et al. (2015). 'Programmed death-1 controls T cell survival by regulating oxidative metabolism' J Immunol 194(12): 5789-5800.

7. Twyman-Saint Victor, C., et al. (2015). 'Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer' Nature 520(7547): 373-377.

體內PD-L1阻斷，流式細胞術

(in vivo PD-L1 blockade, Flow Cytometry)

1. loulou, M., et al. (2016). 'Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells' Nat Commun 7: 10579.

2. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.

3. Rutigliano, J. A., et al. (2014). 'Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells' J Virol 88(3): 1636-1651.

體內PD-L1阻斷，免疫熒光

(in vivo PD-L1 blockade, Immunofluorescence)

1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043.

免疫組織化學（冷凍），免疫熒光

(Immunohistochemistry (frozen), Immunofluorescence)

1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 11(4): 832-840.

更多產品詳情請咨詢 BioXcell 中國授權代理——欣博盛生物

全國服務熱線: 4006-800-892 郵箱: market@neobioscience.com

深圳: 0755-26755892 北京: 010-88594029

廣州：020-87615159 上海: 021-34613729

代理品牌網站: www.neobioscience.com

自主品牌網站: www.neobioscience.net